comparemela.com

Latest Breaking News On - மருந்து வகைப்பாடு - Page 6 : comparemela.com

Non-Hodgkin s Lymphoma Drives The Rituximab Biosimilars Industry - Brazil Business Today

Rituximab Biosimilars Global Market Report 2020-30: Covid 19 Growth And Change The Business Research Company’s Rituximab Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change LONDON, GREATER LONDON, UK, February 8, 2021 /EINPresswire.com/ New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports The rising prevalence of non-Hodgkin’s lymphoma (NHL) is predicted to contribute to the growth of the rituximab biosimilars market. Non-Hodgkin’s lymphoma is a cancer that starts in white blood cells (lymphocytes) that are part of the body’s immune system. In 2018, rituximab-abbs was approved as the first rituximab biosimilars for the treatment of patients with B-cell NHL and adult patients with CD20-positive. According to the National Library of Medicine’s statistics, non-Hodgkin lymphoma was ranked as the 5th to 9th

Biologics Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery - Press Release

Biologics Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery New York, Dec. 30, 2020 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Biologics Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery - https://www.reportlinker.com/p06001237/?utm source=GNW The report covers the following chapters Executive Summary – The executive summary section of the report gives a brief overview and summary of the report Report Structure – This section gives the structure of the report and the information covered in the various sections. Introduction - The introduction section of the report gives brief introduction about segmentation by geography, segmentation by type, by distribution channel, by route of administration, by drug classification, and by mode of purchase.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.